Multifunctional Docetaxel Cholesterol‐Polyethylene Glycol Co‐Modified Poly (N‐Butyl) Cyanoacrylate Nanoparticles for Brain Tumor Therapy
Drug Development Research · 2025
DOI: 10.1002/ddr.70069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Xiao Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing Engineering …. Hauptthemen laut MEDLINE: Docetaxel, Polyethylene Glycols, Brain Neoplasms, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: This research was supported by Capital Science and Technology Leading Talent Training Project [grant numbers Z191100006119017], Capital Medical University Xuan….
Abstract (Originalsprache)
Owing to the presence of the blood‐brain barrier and the lack of significant specificity towards tumor cells after entry into the brain, the unsuccessful delivery of anticancer drugs to the treatment of brain tumors. The hypothesis that cholesterol‐PEG co‐modified poly (N‐butyl) cyanoacrylate nanoparticles (CLS‐PEG NPs) are an effective carrier for the treatment of brain tumors was verified, and the mechanism of its treatment for brain tumors was preliminarily explored. In this study, we used multifunctional poly (N‐butyl) cyanoacrylate nanoparticles modified with cholesterol and polyethylene glycol (PEG) as a drug delivery system to encapsulate the anticancer drug docetaxel (DTX). Cell anti‐proliferation tests showed that CLS‐PEG NPs increased the inhibitory effect of DTX. A pharmacokinetic study indicated that CLS‐PEG NPs achieved sustained release for 8 h. These experimental results demonstrated that CLS‐PEG NPs amplified the concentration of the drug transported to the brain and sustained drug release in the brain. In addition, CLS‐PEG NPs led to better pharmacological efficacy in an orthotopic brain glioma rat model. The survival rate of rats in the CLS‐PEG NPs group was significantly prolonged to 28 d. We also found that CLS‐PEG NPs inhibited M2 microglial polarization. These results indicate that CLS‐PEG NPs are a prospective drug delivery system for targeting brain tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing Engineering Research Center for Nerve System Drugs, Beijing Municipal Geriatric Me…
- Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100193, China.
ORCID-Profile: Lan Zhang
Förderung
- This research was supported by Capital Science and Technology Leading Talent Training Project [grant numbers Z191100006119017], Capital Medical University Xuan…
Zitieren
APA
Hu, X., Yang, F., Liao, Y., Li, L., & Zhang, L. (2025). Multifunctional Docetaxel Cholesterol‐Polyethylene Glycol Co‐Modified Poly (N‐Butyl) Cyanoacrylate Nanoparticles for Brain Tumor Therapy. Drug Development Research. https://doi.org/10.1002/ddr.70069
Vancouver
Hu X, Yang F, Liao Y, Li L, Zhang L. Multifunctional Docetaxel Cholesterol‐Polyethylene Glycol Co‐Modified Poly (N‐Butyl) Cyanoacrylate Nanoparticles for Brain Tumor Therapy. Drug Development Research. 2025. doi:10.1002/ddr.70069
BibTeX
@article{Hu2025,
author = {Hu, Xiao and Yang, Feifei and Liao, Yonghong and Li, Lin and Zhang, Lan},
title = {Multifunctional Docetaxel Cholesterol‐Polyethylene Glycol Co‐Modified Poly (N‐Butyl) Cyanoacrylate Nanoparticles for Brain Tumor Therapy},
journal = {Drug Development Research},
year = {2025},
doi = {10.1002/ddr.70069}
}
EUVIMED